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COMMENTARY

Medicine and Media: The Ranitidine Debate
Jennifer A. Wagner1,2,* and Jennifer M. Colombo1,2

Ranitidine has been the topic of recent media reports. Current
findings, confirmed by the US Food and Drug Administration,
indicate that some ranitidine products contain a substance
that may be carcinogenic. Providers and patients require
additional information on the risks of continuing therapy
vs. the benefits of the medication. This article comments
on what is currently known about the evolving situation of
elevated N-nitrosodimethylamine levels in ranitidine and the
limits of the existing information to assess best practices.
In September 2019, a petition was sent to the US Food and
Drug Administration (FDA) reporting routine testing had
detected N-nitrosodimethylamine (NDMA), a likely human
carcinogen, in excess of 3,000 micrograms (µg) per ranitidine tablet, over 30,000 times the FDA’s permissible daily
intake limit.1 The petitioner suggested that ranitidine is an
unstable molecule capable of reacting with itself in standard
analysis conditions to produce excessive NDMA levels and
requested the FDA take actions to include robust independent chemical testing and verification of pharmaceuticals.
The FDA confirmed some ranitidine products contained
NDMA but categorized the levels as low and further recommended a liquid chromatography-high-resolution mass
spectrometry testing protocol specific for ranitidine, as
there was concern by the FDA that the elevated levels
reported by the petitioner were produced as a direct byproduct of elevated temperatures used in the analysis.2
Ranitidine, an H2-receptor antagonist (H2RA), is very
commonly prescribed for the treatment of gastroesophageal reflux disease (GERD). It is also used for the treatment
of peptic ulcer disease, hypersecretory states, such as
Zollinger-Ellison syndrome, systemic mastocytosis, and prophylaxis of stress ulceration and gastrointestinal bleeding.
GERD is a chronic disorder where gastric contents move
from the stomach back into the esophagus and cause symptoms such as regurgitation, vomiting, feeding refusal, and
poor weight gain in infants and epigastric pain, chest pain,
heartburn, and regurgitation in older children and adults.
Without treatment, GERD can negatively impact quality of
life and is a risk factor for the development of erosive esophagitis, esophageal strictures, and Barrett’s esophagus, a
precancerous lesion. Pediatric and adult GERD clinical
practice guidelines suggest nonpharmacologic treatments
as first-line therapy; however, if these treatments fail, medications such as H2RAs and/or proton pump inhibitors (PPIs)
are recommended. H2RAs selectively block the histamine-2
1

receptor in gastric parietal cells, resulting in the decreased
production of gastric acid. H2RAs are more effective than
placebo in improving symptoms, increasing intragastric pH,
and improving histologic changes due to acid reflux.
Average NDMA levels found in 7 of the 14 ranitidine products tested by the FDA yielded ranges from 0.15–0.86 µg
per tablet or standard dose of syrup formulation, noted to be
above the acceptable daily intake (ADI) level of 0.096 µg set
forth by the FDA,2 but significantly lower than reported by the
petitioner. Several ranitidine products contained well below
the recommended maximum daily intake levels. Various
formulations of nizatidine, a structurally similar H2-receptor
antagonist, contained NDMA but below threshold levels. The
FDA initially asked manufacturers to conduct their own laboratory testing to examine levels of NDMA in ranitidine and
nizatidine and send samples to be tested by the FDA. The
agency asked for voluntary recalls by manufacturers of products with elevated levels, although many manufacturers had
already begun recalls while several retailers discontinued
ranitidine sales. The agency has since asked for manufacturers to test all lots of ranitidine and nizatidine before releasing
to consumers and to retain lots with levels above the ADI and
report those to the FDA. Furthermore, the FDA reported that
no additional NDMA was generated when the products were
subjected to the agency’s simulated gastric and intestinal
fluid models but that testing the drugs in the human body is
required to fully understand if ranitidine forms NDMA.2 This
was in contrast to the petitioner’s claims that high levels of
NDMA resulted when ranitidine was exposed to a simulated
gastric fluid model with the addition of various concentrations of sodium nitrite, although the amounts of sodium nitrite
added may not support the claim of biologically relevant
conditions.3 The FDA has reiterated that levels in affected
ranitidine are similar to those expected from ingestion of
common nitrite-rich foods, such as grilled or smoked meats.
In 2018, the FDA confirmed NDMA contamination in valsartan, an angiotensin II receptor blocker leading to recalls.
Valsartan products contained as much as 20 µg per tablet
of NDMA likely resulting from a change in the manufacturing process. In December 2019, several metformin products
marketed by Singapore-based manufacturers were found to
contain elevated NDMA levels. The FDA is investigating, but
currently has not recalled metformin on the US market.
Human NDMA exposure occurs through both exogenous
and endogenous pathways. NDMA is a known byproduct
from pesticide manufacturing, tanneries, and tire plants,
and is found in multiple food and beverages, including
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processed/cured meats and smoked/salted fish, as well as
malt beverages. Additional sources include toiletry products, cigarette smoke, and drinking water. In animal studies,
ingested NDMA is absorbed extensively, distributed widely,
cleared rapidly via hepatic and extrahepatic metabolism,
and excreted in the urine or exhaled. Intragastric formation
of NDMA in humans has been reported to occur in vitro
under physiological conditions.4 Various animal species
have developed cancers in the liver, lung, stomach, respiratory tract, kidney, and blood vessels secondary to NDMA,
and the International Agency for Research on Cancer has
classified NDMA as group 2A, “probably carcinogenic to humans.”5 Three studies have reported that NDMA increases
the risk of gastrointestinal cancer in humans,6 yet additional
evidence of carcinogenicity in humans is sparse.
Generally, standard risk assessments of carcinogens
assume that cancer risk increases as a function of cumulative dose. The NDMA ADI limit set by the FDA is a daily
exposure at a theoretically calculated level that approximates a 1:100,000 cancer risk after 70 years of exposure.
These risk levels represent a small theoretical increase in
risk when compared with overall human lifetime incidence of
developing any type of cancer, which is > 1 in 3. For certain
medications, calculation of a higher daily intake of impurities
can be considered for brief exposures because the cumulative dose would be significantly less than a daily treatment
regimen of 70 years at the ADI limit. Average daily dietary
intake of NDMA for US adults aged 20–49 is an estimated
0.06 µg.7
The agency has stopped short of recommending discontinuation of ranitidine, instead suggesting that concerned
patients should discuss other treatment options with their
providers, or if taking an over the counter ranitidine product, to consider using other over the counter medications.
Suggested ranitidine treatment duration for GERD is only
4–8 weeks with symptom reassessment to avoid unnecessary long-term use, and tachyphylaxis does occur with
prolonged use sometimes rendering it ineffective. Alternatives
to ranitidine include other H2RAs (cimetidine and famotidine)
and PPIs (omeprazole, lansoprazole, and esomeprazole).
Ranitidine and famotidine seem to be equally effective.
Current clinical practice guidelines indicate that H2RAs play a
secondary role in the treatment of GERD; PPIs have become
the mainstay of treatment.8 Notably, neither the FDA nor the
petitioner detected NDMA in structurally dissimilar H2RAs famotidine and cimetidine (Figure 1) or in several PPIs.
Little evidence is available to interpret associations among
NDMA, ranitidine, and carcinogenicity. High doses of ranitidine in combination with nitrite was found to produce DNA
fragmentation in the liver and gastric mucosa in rodents.9 A
recent study conducted in humans found that urinary NDMA
excretion over a 24-hour period following an orally administered dose of ranitidine increased from an average baseline
of 0.11 µg/24 hour to a range of 19.5–47.6 µg/24 hour.10 The
authors argue the urinary measurement represents a lower
bound estimate to systemic NDMA exposure. Additionally,
the researchers documented production of NDMA by nitrosation of ranitidine under stomach-relevant pH conditions in
vitro and proposed a mechanism of NDMA formation from
ranitidine (Figure 2).
Clinical and Translational Science

Figure 1 Structures of N-nitrosodimethylamine and H2- receptor
antagonists.

The FDA requires extensive safety data be produced prior
to any new drug approval, but cancer risks are difficult to
determine in studies that are inherently short and conducted
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Figure 2 Proposed mechanism for the formation of N-nitrosodimethylamine (NDMA) from ranitidine in gastric conditions (Zeng &
Mitch10. Used by permission of Oxford University Press).

primarily in animals. Moreover, drugs that have been on the
market for many decades were originally dependent on testing methodologies that may be outdated. Elevated NDMA
levels were observed in both tablet and syrup formulations,
which lends further evidence that the NDMA formation is a
result of an issue intrinsic to the active pharmaceutical ingredient. Regardless of the controversy that exists regarding
the source and amounts of NDMA measured in ranitidine,
the FDA has documented levels higher than its own recommended limit in some products. However, guidance on ADI
limits as related to traditionally prescribed length of treatment courses (significantly less than lifetime exposure) may
allow the prescriber to have a more thorough appreciation of
risk. Setting the ADI equal to the maximum amount allowed
in a standard dose does not allow for any exposures from
additional sources. Additionally, whether or not ranitidine
can react with itself, theoretically any nitroso donor reacting
with ranitidine may be capable of producing NDMA under
favorable conditions. Clearly, the potential cancer risk of
various treatment lengths of ranitidine should be balanced
against its benefits of therapeutic use, but complete data for
a comprehensive risk assessment are lacking.
Additional studies, such as measuring NDMA concentrations in body fluids following ranitidine or radiolabeled
ranitidine administration, to understand the load of NDMA
would be beneficial, and epidemiological studies evaluating
cancer risk attributable to long-term use of ranitidine and
NDMA are necessary. Research examining production of
NDMA is imperative, and manufacturers and the FDA should
have a high index of suspicion of elevated levels in additional
pharmaceuticals given NDMA may result from production
processes or potentially from endogenous processes. In the
meantime, with acceptable alternatives both in the same
class and in additional classes, the benefits of continuing
treatment with ranitidine may not clearly outweigh the risks.
As the FDA continues to investigate NDMA’s association
to ranitidine and provide clear and actionable information,
the actions of the manufacturers and retailers may limit patients’ and providers’ medication treatment options. Media
coverage to consumers may be misinterpreted as clear
evidence of potential harm with continued use. However,
removing medications from the market prematurely can
result in critical drug shortages of alternative medications
and may pose greater harm to patients who require these
medications. Additionally, prescribing alternative medications may be difficult given insurance medication coverage

and may delay necessary treatment. Manufacturers, regulators, and providers must help families understand the
risks and benefits when considering treatment with ranitidine and continuously evaluate the efficacy and safety of
the medications prescribed using the most accurate available information, but current resolution of the various issues
involved may take considerable time leaving providers lacking necessary information to quickly and accurately counsel
patients.
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